PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy

British Journal of Haematology

Volumn 180, Issue 5, 2018, Pages 752-755

  Nishino, Mizuki ^a   Ramaiya, Nikhil H ^a   Hatabu, Hiroto ^a   Hodi, F Stephen ^b   Armand, Philippe F ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

immune related adverse event; lymphoma; PD 1 inhibitor; pembrolizumab; pneumonitis

Indexed keywords

CARMUSTINE; PEMBROLIZUMAB; PREDNISONE; CORTICOSTEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FEMALE; HUMAN; LETTER; LYMPHOMA; MALE; PNEUMONIA; PRIORITY JOURNAL; RETREATMENT; CHEMICALLY INDUCED; MIDDLE AGED;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PNEUMONIA;

EID: 85001996807     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14441     Document Type: Letter

References (9)

1. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.J., Felip, E., Lee, J.S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.C., Dolled-Filhart, M., Rutledge, R.Z., Zhang, J., Lunceford, J.K., Rangwala, R., Lubiniecki, G.M., Roach, C., Emancipator, K. & Gandhi, L. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. New England Journal of Medicine, 372, 2018–2028.
2. Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., Powderly, J.D., Heist, R.S., Carvajal, R.D., Jackman, D.M., Sequist, L.V., Smith, D.C., Leming, P., Carbone, D.P., Pinder-Schenck, M.C., Topalian, S.L., Hodi, F.S., Sosman, J.A., Sznol, M., McDermott, D.F., Pardoll, D.M., Sankar, V., Ahlers, C.M., Salvati, M., Wigginton, J.M., Hellmann, M.D., Kollia, G.D., Gupta, A.K. & Brahmer, J.R. (2015) Overall survival and long-term safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology, 33, 2004–2012.
3. Lane, A.A., Armand, P., Feng, Y., Neuberg, D.S., Abramson, J.S., Brown, J.R., Fisher, D.C., LaCasce, A.S., Jacobsen, E.D., McAfee, S.L., Spitzer, T.R., Freedman, A.S. & Chen, Y.B. (2012) Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leukaemia & Lymphoma, 53, 1130–1136.
4. Nishino, M., Sholl, L.M., Hodi, F.S., Hatabu, H. & Ramaiya, N.H. (2015a) Anti-PD-1-related pneumonitis during cancer immunotherapy. New England Journal of Medicine, 373, 288–290.
5. Nishino, M., Boswell, E.N., Hatabu, H., Ghobrial, I.M. & Ramaiya, N.H. (2015b) Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom Macroglobulinemia as a Paradigm. Oncologist, 20, 1077–1083.
6. Nishino, M., Chambers, E.S., Chong, C.R., Ramaiya, N.H., Gray, S.W., Marcoux, J.P., Hatabu, H., Janne, P.A., Hodi, F.S. & Awad, M.M. (2016a) Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunology Research, 4, 289–293.
7. Nishino, M., Brais, L.K., Brooks, N.V., Hatabu, H., Kulke, M.H. & Ramaiya, N.H. (2016b) Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. European Journal of Cancer, 53, 163–170.
8. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., Shaheen, M., Ernstoff, M.S., Minor, D., Salama, A.K., Taylor, M., Ott, P.A., Rollin, L.M., Horak, C., Gagnier, P., Wolchok, J.D. & Hodi, F.S. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 372, 2006–2017.
9. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. & Sznol, M. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 366, 2443–2454.